Key result
Aspirin demonstrates potential for the prevention and treatment of colorectal cancer, with emerging biomarkers such as PIK3CA mutation status and HLA class I expression offering opportunities to personalize therapy and minimize bleeding risks.
Why the study?
Does aspirin improve prevention and treatment of colorectal cancer in specific biomarker-defined populations?
Does aspirin improve prevention and treatment of colorectal cancer in specific biomarker-defined populations?
Clinical, molecular, and genetic biomarkers such as PIK3CA mutation status and COX-2 expression may help personalize aspirin therapy for colorectal cancer to optimize the balance of benefits and risks.
Aspirin for colorectal cancer remains investigational; leaves open biomarker-guided trials to confirm benefit-risk balance.
There is now a considerable body of data supporting the hypothesis that aspirin could be effective in the prevention and treatment of colorectal cancer, and a number of phase III randomised controlled trials designed to evaluate the role of aspirin in the treatment of colorectal cancer are ongoing. Although generally well tolerated, aspirin can have adverse effects, including dyspepsia and, infrequently, bleeding. To ensure a favourable balance of benefits and risks from aspirin, a more personalised assessment of the advantages and disadvantages is required. Emerging data suggest that tumour PIK3CA mutation status, expression of cyclo-oxygenase-2 and human leukocyte antigen class I, along with certain germline polymorphisms, might all help to identify individuals who stand to gain most. We review both the underpinning evidence and current data, on clinical, molecular and genetic biomarkers for aspirin use in the prevention and treatment of colorectal cancer, and discuss the opportunities for further biomarker research provided by ongoing trials.
No takes yet. Share an insight, caveat, or question.
Coyle et al. (2016) conducted a review in Colorectal cancer. Aspirin was evaluated. Aspirin demonstrates potential for the prevention and treatment of colorectal cancer, with emerging biomarkers such as PIK3CA mutation status and HLA class I expression offering opportunities to personalize therapy and minimize bleeding risks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: